MACOP-B vs F-MACHOP Regimen in the Treatment of High-Grade Non-Hodgkin's Lymphomas

References

• Coltman I.C.A., Jr, Dahlberg S., Jones S.E., . CHOP is curative in thirty percent of patients with large cell lymphoma: A twelve-year South West Oncology Group follow-up. Update on treatment for diffuse large cell lymphoma, AT Skarin, et al. Park Row, New York 1986; 71–77
   Google Scholar
• Coleman M. Chemotherapy of large cell lymphoma: optimism and caution. Ann. Intern. Med. 1985; 103: 140–142
   PubMed Web of Science ®Google Scholar
• Coleman M., Gerstein G., Topilow A., et al. Advances in chemotherapy for large cell lymphoma. Sem. Hematol. 1987; 24(Suppl 1)8–20
   PubMedGoogle Scholar
• Coleman M., Armitage J.O., Gaynor M., et al. The COP-BLAM programs: evolving chemotherapy concepts in large cell lymphoma. Sem. Hematol 1988; 25(Suppl 2)23–33
   PubMed Web of Science ®Google Scholar
• Connors J.M., Klimo P. MACOP-B chemotherapy for malignant lymphomas and related conditions: 1987 update and additional observations. Sem. Hematol 1988; 25(Suppl 2)41–46
   PubMed Web of Science ®Google Scholar
• Klimo P., Connors J.M. MACOP-B chemotherapy for the treatment of diffuse large cell lymphoma. Ann. Intern. Med. 1985; 102: 596–602
   PubMed Web of Science ®Google Scholar
• Lee R., Cabanillas F., Bodey G., Frereich E.J. A 10-year update of CHOP-Bleo in the treatment of diffuse large cell lymphoma. J. Clin. Oncol 1986; 4: 1455–1461
   PubMed Web of Science ®Google Scholar
• Schein P.S., De Vita V.T., Hubbard S., et al. Bleomycin, Adriamycin, Cyclophosphamide, Vincristine and prednisone (BACOP). Blood 1977; 49: 759–770
   PubMed Web of Science ®Google Scholar
• Mazza P., Lauria F., Gherlinzoni F., Fiacchini M., Galieni P., Tura S. Non-Hodgkin's lymphomas: prognostic feature of 55 patients treated with MEVAP chemotherapy. Haematologica 1984; 69: 178–187
   PubMedGoogle Scholar
• Fischer R.I., DeVita V.T., Jr, Hubbard S.M., et al. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of PROMACE and MOPP chemotherapy. Ann. Intern. Med. 1983; 98: 304–309
   PubMed Web of Science ®Google Scholar
• Oster W., Forsthuber T., Henne Keuser H.H., et al. MACOP-B chemotherapy for the treatment of high grade and intermediate grade non-Hodgkin's lymphomas. Blut 1990; 60: 23–27
   PubMedGoogle Scholar
• Mazza P., Bocchia M., Zanchini R., et al. MN (N = NOVANTRONE)COP-B therapy on high and intermediate grade non-Hodgkin's lymphoma: an alternative to MA(A = ADRI-AMYCIN)COP-B?. Haematologica 1991; 2: 234–240
   Google Scholar
• Canellos G.P., Skarin A.T., Klatt M.M., et al. The m-BACOD combination chemotherapy regimen in the treatment of diffuse large cell lymphoma. Sem. Hematol 1987; 24(Suppl 1)2–6
   PubMedGoogle Scholar
• Skarin A.T., Canellos G.P., Rosenthal D.S., et al. Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). J. Clin. Oncol 1983; 1: 91–95
   PubMed Web of Science ®Google Scholar
• Fisher R.I., De Vita V.T., Hubbard S.M., et al. Randomized trial of Pro MACE-MOPP Vs Pro MACE-CytaBOM in previously untreated advanced stage, diffuse aggressive lymphomas. Proc. Am. Soc. Clin. Oncol. 1984; 3: 242
   Google Scholar
• Miller T.P., Dana B.W., Weick J.K., et al. Southwest Oncology Group Clinical trials for intermediate and high-grade non-Hodgkin's lymphomas. Sem. Hematol 1988; 2(Suppl 2)17–22
   Google Scholar
• Gherlinzoni F., Guglielmi C., Mazza P., Amadori S., Mandelli F., Tura S. Phase III comparative trial (m-BACOD vs m-BNCOD) in the treatment of Stage II to IV non-Hodgkin's lymphomas with intermediate- or high-grade histology. Semin. Oncol 1990; 17(Suppl 10)3–9
   PubMedGoogle Scholar
• Longo D.L., DeVita V.T., Jr., Duffey P.L., et al. Superiority of Pro-MACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. J. Clin. Oncol 1991; 9: 25–38
   PubMed Web of Science ®Google Scholar
• Chisesi T., Santini G., Capnist G., et al. Pro MACE-MOPP Vs MACOP-B in high grade non-Hodgkin's lymphomas a randomized study in a multicenter cooperative study group (NHLCSG). Leukemia 1991; 5(Suppl 1)107–111
   PubMedGoogle Scholar
• Fisher R.I., Gaynor E.R., Dhalberg S., et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N. Engl. J. Med. 1993; 329: 1002–1006
   Web of Science ®Google Scholar
• Guglielmi C., Amadori S., Anselmo A.P., et al. Sequential combination chemotherapy of high grade non-Hodgkin's lymphoma with 5-fluorouracil, methotrexate cytosine-arabinoside, cyclophosphamide, doxorubicin, vincristine and prednisone (F-MACHOP). Cancer Invest. 1987; 5: 159–169
   PubMed Web of Science ®Google Scholar
• Guglielmi C., Martelli M., Mantovani L., et al. Early pathologic response evaluation in high-grade non Hodgkin's lymphomas treated with F-MACHOP. Proc. Am. Soc. Clin. Oncol. 1989; 8: 259
   Google Scholar
• Guglielmi C., Martelli M., Amadori S., Mandelli F. The F-MACHOP chemotherapy regimen in advanced diffuse aggressive lymphomas: long-term results. Ann. Oncol. 1991; 2: 365–371
   PubMed Web of Science ®Google Scholar
• Stansfeld A.G., Diebold J., Kapanci Y., et al. Updated Kiel classification for lymphomas. Lancet 1988; i: 292–293
   Google Scholar
• Carbone P.P., Kaplan H.S., Musshoff K., et al. Report of the committee on Hodgkin's disease staging classification. Cancer Res. 1971; 31: 1860–1861
   PubMed Web of Science ®Google Scholar
• Oken M., Creech R., Tormey D. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol 1982; 5: 649–655
   PubMed Web of Science ®Google Scholar
• Velasquez W.S., Cabanillas F., Fridrik M., et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose ARA-C and dexamethasone (DHAP). Blood 1988; 71: 117–123
   PubMed Web of Science ®Google Scholar
• Tura S., Mazza P., Gherlinzoni F., et al. High-dose therapy followed by autologous bone marrow transplantation (ABMT) in previously untreated non-Hodgkin's lymphoma. Scand. J. Haematol. 1986; 37: 347–353
   PubMedGoogle Scholar
• Hryniuk W.M., Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J. Clin. Oncol. 1984; 2: 1281–1288
   PubMed Web of Science ®Google Scholar
• Cox D.R. Analysis of Binary Data. Methuen, LondonUK 1970
   Google Scholar
• Cox D.R. Regression models and life tables (with discussion). J. R. Stat. Soc. B. 1972; 34: 187–220
   Google Scholar
• Kaplan E.L., Meier P. Non-parametric estimation from incomplete observations. J.A.M.A. 1958; 53: 457–481
   Web of Science ®Google Scholar
• WHO handbook for reporting results of cancer treatment. WHO offset publication No 48. WHO, GeneveSwitzerland 1979
   Google Scholar
• Goldie J.H., Coldman A.J., Gudauskas G.A. Rationale for the use of alternating non cross-resistant chemotherapy. Cancer Treat. Rep. 1982; 66: 439–449
   PubMedGoogle Scholar
• Tura S., Zinzani P.L., Mazza P., et al. ABMT vs DHAP in residual disease following third generation regimens for aggressive non-Hodgkin's lymphomas. Blood 1992; 80(Suppl 1)157a
   Google Scholar
• Velasquez W.S., Jagannath S., Tucker S.L., et al. Risk classification as the basis for clinical staging of diffuse large-cell lymphoma derived from 10-year survival data. Blood 1989; 74: 551–557
   PubMed Web of Science ®Google Scholar
• Coiffier B., Gisselbrecht C., Vose J.M., et al. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. J. Clin. Oncol. 1991; 9: 211–219
   PubMed Web of Science ®Google Scholar
• Hoskins P.J., Ng V., Spinelli J.J., Klimo P., Connors J.M. Prognostic variables in patients with diffuse large-cell lymphoma treated with MACOP-B. J. Clin. Oncol. 1991; 9: 220–226
   PubMed Web of Science ®Google Scholar
• Pileri S., Bocchia M., Baroni C.D., et al. Anaplastic large cell lymphoma (CD30 +/Ki - 1+): results of a prospective clinico-pathological study of 69 cases. Br. J. Haematol 1994; 86: 513–523
   PubMed Web of Science ®Google Scholar
• Shipp M.A., et al. A predictive model for aggressive non-Hodgkin's lymphoma. New Engl. J. Med. 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar